Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the American Medical Directors Association
Alzheimer's Disease International. World Alzheimer Report. 2009. Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed December 2, 2012.
- Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study.Int J Geriatr Psychiatry. 2008; 23: 170-177
National Institute for Health and Clinical Excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care. Available at: https://www.nice.org.uk/guidance/cg42. 2006. Accessed June 16, 2014.
- Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.Am J Geriatr Psychiatry. 2006; 14: 561-572
Alzheimer's Society Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. Available at: http://www.alzheimers.org.uk/bpsdguide. 2012. Accessed April 23, 2014.
- Neuroleptic drugs in dementia: Benefits and harm.Nature Rev Neurosci. 2006; 7: 492-500
- Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials.Am J Geriatr Psychiatry. 2006; 14: 191-210
- Management of agitation and aggression associated with Alzheimer disease.Nat Rev Neurol. 2009; 5: 245-255
- Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.Expert opinion on drug safety. 2011; 10: 35-43
- Antipsychotics in dementia: Prevalence and quality of antipsychotic drug prescribing in UK mental health services.Br J Psychiatry. 2012; 201: 221-226
- Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial.BMJ. 2005; 330: 874
- Nature reviews Neuroscience.N Engl J Med. 2006; 355: 1525-1538
- Withdrawal of neuroleptic medications from institutionalized dementia patients: Results of a double-blind, baseline-treatment-controlled pilot study.J Geriatr Psychiatry Neurol. 1997; 10: 119-126
- A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome.J Clin Psychiatry. 2004; 65: 114-119
- A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).PLoS Med. 2008; 5: e76
- The dementia antipsychotic withdrawal trial (DART–AD): Long-term follow-up of a randomised placebo-controlled trial.Lancet Neurol. 2009; 8: 151-157
- A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.Int J Geriatr Psychiatry. 2011; 26: 937-943
- Relapse risk after discontinuation of risperidone in Alzheimer's disease.N Engl J Med. 2012; 367: 1497-1507
- Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial.BMJ. 2006; 332: 756-761
- Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: A controlled, double-blind study.Arch Intern Med. 1999; 159: 1733-1740
- Top cited papers in International Psychogeriatrics: 6a. Quality of life for people with dementia living in residential and nursing home care: The impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs.Int Psychogeriatr/IPA. 2009; 21: 1026-1030
- Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double–blind placebo controlled trial.PLoS One. 2012; 7: e35185
- Memantine for dementia.Cochrane Database Syst Rev. 2006; : CD003154
- Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies.J Clin Psychiatry. 2008; 69: 341-348
- Donepezil and memantine for moderate-to-severe Alzheimer's disease.N Engl J Med. 2012; 366: 893-903
- Clinical diagnosis of Alzheimer's disease: Report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.Neurology. 1984; 34: 939-944
- A description of agitation in a nursing home.J Gerontol. 1989; 44: M77-M84
- The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.Int J Geriatr Psychiatry. 2000; 15: 656-661
- The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia.Neurology. 1994; 44: 2308-2314
- “Mini–mental state.” A practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res. 1975; 12: 189-198
- The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies.Acta Neurol Scand. 1997; 96: 366-371
- Validity and reliability of the Alzheimer's Disease Cooperative Study–Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.Alzheimer Dis Assoc Disord. 1997; 11: S22-S32
- The GDS/FAST staging system.Int Psychogeriatr/IPA. 1997; 9: 167-171
Health & Social Care Information Centre. National Dementia and Antipsychotic Prescribing Audit. Available at: http://www.hscic.gov.uk/dementiaaudit. 2012. Accessed September 8, 2014.
ZW has received funding for travel, consultancy, and speaker fees and research support from GE Healthcare, consultancy fees from Bayer Healthcare and Novartis, and research support from Lundbeck (Grant no:11829A). AC has received speaking fees and consultancy honoraria from Novartis, Lundbeck, Bial, and Acadia. CB has received speaking fees and consultancy honoraria from Acadia, Lundbeck, Bristol-Myer Squibb, Napp, Takeda, Onsaka, Synexus, and Novartis. AB is National Clinical Director for Dementia for NHS England and has received honoraria for writing of court reports and Driver and Vehicles Licensing Agency reports. The other authors report no competing interests.
The investigators thank Lundbeck pharmaceutical company for funding the MAIN-AD study. The funding source contributed to the initial design of the trial protocol, had no direct role in the trial and did not contribute to interpretation of the results or writing of the manuscript.
AC and CB thank the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London for supporting their input. AT acknowledges the research was supported by NIHR Newcastle Biomedical Research Unit. The investigators thank DeNDRoN for support at the Newcastle, Oxford, and Essex sites.
This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.